Fig 1.
The health-state structure was published previously as part of the UK National Institute for Care and Excellence single technology appraisal committee papers [22]. PFS, progression free survival; TTP, time to progression; PPS, post-progression survival.
Table 1.
Parameters of survival curve.
Table 2.
Model parameters and distributions.
Table 3.
Base case results: Discounted cost-effectiveness of durvalumab.
Fig 2.
Tornado diagram of one-way sensitivity analysis.
PF, progression free; IMRT, Intensity modulated radiotherapy; BSC, best supportive care.
Fig 3.
Cost-effectiveness plane scatter plot.
Fig 4.
Cost-effectiveness acceptable curve.
The acceptability curve shows the probability of a treatment being cost-effective over a range of willingness-to-pay thresholds. The curve shows that BSC is the most likely to be cost-effective until a willingness-to-pay threshold of 200,000 yuan is reached, after which durvalumab is most likely to be cost-effective.
Table 4.
Comparison of cost-effectiveness studies on durvalumab.